Jefferies Downgrades Aegerion Pharmaceuticals To Hold

Analysts at Jefferies downgraded Aegerion Pharmaceuticals AEGR from Buy to Hold. The price target for Aegerion Pharmaceuticals has been lowered from $61.00 to $24.00. Aegerion Pharmaceuticals shares have dropped 58.68% over the past 52 weeks, while the S&P 500 index has surged 13.56% in the same period. Aegerion Pharmaceuticals' shares fell 31.28% to $23.51 in pre-market trading.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: DowngradesAnalyst RatingsJefferies
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!